Neumora Therapeutics (NMRA) Stock: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$0.42
-0.05 (-10.54%)
▼
5d:
+17.35%
30d:
-46.56%
90d:
-73.33%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NMRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NMRA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $0.42, which is considered oversold relative to its 30-day fair value range of $0.43 to $0.75.
Technical Outlook: Technically, NMRA is in a strong downtrend. Immediate support is located at $0.32, while resistance sits at $0.51. Short-term momentum is weak, with the stock down 10.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.14 (+1376.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NMRA is in a strong downtrend. Immediate support is located at $0.32, while resistance sits at $0.51. Short-term momentum is weak, with the stock down 10.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.14 (+1376.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.43 -
$0.75
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.5%)
- BULLISH: Trading 1376.7% below Wall St target ($6.14)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.43 -
$0.75
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.32
Resistance Level
$0.51
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.62
Wall Street Target
$6.14
(+1376.7%)
Share & Embed Analysis
Last updated: October 22, 2026 8:55 AM ET
Data refreshes hourly during market hours. Next update: 9:55 AM
Data refreshes hourly during market hours. Next update: 9:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 71 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 50 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 63 BUY |